Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492830 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00492830 is a Phase 1 study that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 19 participants.
The verdict
NCT00492830, a Phase 1 study, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
Interventions
- DRUG TRC093 recombinant humanized IgG1k monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00492830
The ClinicalTrials.gov registry entry for NCT00492830 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRC093 recombinant humanized IgG1k monoclonal antibody is the first listed.
NCT00492830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00492830 about?
NCT00492830 is a clinical study titled "Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors". This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
What is the current status of trial NCT00492830?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2007-06. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00492830?
The interventions under investigation include: TRC093 recombinant humanized IgG1k monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT00492830?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.